ZIOPHARM Oncology Inc (ZIOP) : 4 analysts are covering ZIOPHARM Oncology Inc (ZIOP) and their average rating on the stock is 2.5, which is read as a Buy. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
ZIOPHARM Oncology Inc (ZIOP) : The consensus price target for ZIOPHARM Oncology Inc (ZIOP) is $14 for the short term with a standard deviation of $9.9. The most optimist securities analyst among the 2 who monitor the stock believes that the stock can reach $21, however, the pessimist price target for the company is $7.
Shares of ZIOPHARM Oncology, Inc. rose by 0.52% in the last five trading days and 25.11% for the last 4 weeks. ZIOPHARM Oncology, Inc. has dropped 16.95% during the last 3-month period . Year-to-Date the stock performance stands at -29.84%. ZIOPHARM Oncology Inc (NASDAQ:ZIOP): On Tuesdays trading session , Opening price of the stock was $5.9 with an intraday high of $5.9992. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $5.75. However, the stock managed to close at $5.83, a loss of 1.19% for the day. On the previous day, the stock had closed at $5.9. The total traded volume of the day was 1,150,280 shares.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).